The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 15, 2022

Filed:

Oct. 24, 2019
Applicant:

The Board of Trustees of the University of Illinois, Urbana, IL (US);

Inventors:

Bellur Prabhakar, Oak Brook, IL (US);

Sidney Hopps, River Forest, IL (US);

Aditi Mathur, Buffalo Grove, IL (US);

Fei Yue, North Riverside, IL (US);

Shikha Saini, Chicago, IL (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07H 21/02 (2006.01); C07H 21/04 (2006.01); A61K 31/7105 (2006.01); C12N 15/113 (2010.01); A61P 35/00 (2006.01); A61K 9/127 (2006.01); C12N 15/63 (2006.01); A61P 31/00 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/7105 (2013.01); A61K 9/127 (2013.01); A61P 31/00 (2018.01); A61P 35/00 (2018.01); C12N 15/113 (2013.01); C12N 15/63 (2013.01); A61K 45/06 (2013.01); C12N 2310/11 (2013.01); C12N 2310/14 (2013.01); C12N 2310/531 (2013.01); C12N 2320/31 (2013.01);
Abstract

Compositions and methods for treating cancers are provided which comprise administering a combination of antineoplastic agents, wherein the combination comprises protein kinase inhibitor, anthracycline, nucleoside analog, apoptosis-inducing molecular therapeutic or alkylating agent chemotherapeutics and one or more nucleic acid molecules capable of down-regulating expression of at least one splice variant of the IG20 gene, and wherein not all splice variants of the IG20 gene are down-regulated. Preferably, the splice variant of the IG20 gene is a MADD splice variant and the nucleic acid molecules are siRNA, shRNA and antisense oligonucleotides which comprise a nucleic acid sequence complementary to a nucleic acid sequence of exon 13L of the MADD splice variant or to an mRNA transcript of exon 13L of the MADD splice variant.


Find Patent Forward Citations

Loading…